Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Acute myeloid leukemia and MDS
Phase I: Blinatumomab, bispecific CD19-directed antibody, combined with early memory T-cell infusion protocol
This Phase I trial at St. Jude Children's Research Hospital tests the safety and feasibility of an early CD45RA-depleted donor lymphocyte infusion following a TCRαβ-depleted haploidentical transplant in patients with…
NCT07052370 First-in-human - Trial result Spotlight
Breast cancer
Biomarker Duo sTILs + TNBC-DX Flags 91% pCR With PD-1/Carbo-Taxane in Early TNBC
Pembrolizumab, a PD-1 antibody, combined with neoadjuvant docetaxel-carboplatin (TCb + Pem) in the Phase II NeoPACT study (NCT03639948, n = 115) for stage I-III triple-negative breast cancer delivered a 58% overall…
NCT03639948 - Trial result
Non-small cell lung cancer
Gut-Targeted Vancomycin Boosts SBRT Survival in Early-Stage NSCLC
Vancomycin, a non-absorbed antibiotic that selectively depletes gram-positive gut bacteria, was paired with stereotactic body radiotherapy (SBRT) in a randomized pilot (NCT03546829) of medically inoperable stage I–II…
NCT03546829 - Trial result
Non-small cell lung cancer
Divarasib Delivers 56% ORR and ~14 mo PFS in KRAS G12C NSCLC
Divarasib (GDC-6036) is an oral, covalent KRAS G12C inhibitor; targeting the ~11‑13% of NSCLC tumors that carry this mutation; in the GO42144 Phase I dose-escalation/expansion trial (NCT04449874) 65 previously…
NCT04449874 - Trial result
Melanoma
Neoadjuvant Nivo + Relatlimab (PD-1 / LAG-3) Yields 80% 4-Year EFS in Resectable Stage III-IV Melanoma
Relatlimab (anti-LAG-3) plus nivolumab (anti-PD-1) was given peri-operatively in the single-arm Phase II NCT02519322 study. Thirty patients with resectable stage III/IV melanoma received two neoadjuvant doses,…
NCT02519322 - Trial result
Melanoma
Oncolytic HSV‑1 RP1 plus PD‑1 blockade yields 33% ORR in PD‑1‑refractory melanoma
Vusolimogene oderparepvec (RP1) is an intratumoral HSV‑1 oncolytic virus engineered to secrete GM‑CSF and drive syncytia formation; in the single‑arm Phase II IGNYTE cohort (NCT03767348) it was paired with nivolumab…
NCT03767348 - Trial result
Colorectal cancer
Biweekly capecitabine + oxaliplatin (CAPOX) slashes cytopenias while matching 3‑yr DFS in high‑risk stage II/III colorectal cancer
CAPOX couples oral fluoropyrimidine (capecitabine) with platinum DNA‑crosslinking agent oxaliplatin; the standard adjuvant schedule is every 3 weeks. In the Chinese phase II RCT NCT03564912, 160 post‑surgery…
NCT03564912 - Trial result Spotlight
Stomach and esophageal cancer
EGFR×HER3 bispecific ADC logs 40% responses in PD‑1‑refractory metastatic ESCC
BL‑B01D1 pairs an EGFR‑HER3 bispecific antibody with a cleavable topoisomerase I payload; in the phase 1b NCT05262491 study, 82 heavily pre‑treated ESCC patients received 2.0 or 2.5 mg/kg every 3 weeks. Overall…
NCT05262491 - Trial result
Stomach and esophageal cancer
Regorafenib Benefit Survives Bias-Checks: HR 0.71 in Pooled INTEGRATE Phase 2/3 Gastric Cancer Data
Regorafenib, an oral multikinase inhibitor, was re-examined across the seamless INTEGRATE program—183 refractory gastric or gastro-oesophageal junction cancer patients from phase 2 (with post-progression crossover)…
- Trial result
Ovarian cancer
Avutometinib + defactinib delivers 31% ORR (44% in KRAS‑mut) in recurrent low‑grade serous ovarian cancer (LGSOC)
Avutometinib is an oral “RAF/MEK clamp” that locks MEK in an inactive state while preventing RAF feedback, and defactinib blocks focal‑adhesion kinase; together they target MAPK signaling and stromal crosstalk. In…
- Trial result
Ovarian cancer
PARP-VEGF Duo Niraparib + Bevacizumab Posts 61-Month OS in Advanced Ovarian Cancer Maintenance
Niraparib, an oral PARP inhibitor, paired with the anti-VEGF antibody bevacizumab was evaluated in the single-arm phase 2 OVARIO trial (NCT03326193). Among 105 stage IIIB-IV patients who achieved at least a partial…
NCT03326193 - Trial result
Lymphoma
Brentuximab Vedotin + Pembrolizumab Yields 88% Pre-ASCT CMR in R/R cHL
Brentuximab vedotin (BV), a CD30-directed ADC, plus the PD-1 inhibitor pembrolizumab was retrospectively used as salvage in 24 heavily pre-treated relapsed/refractory classical Hodgkin lymphoma patients prior to…
- New trial Spotlight
Breast cancer
Phase 3 Sac-TMT ADC: TROP2-directed antibody-drug conjugate.
This Phase 3 trial compares sac-TMT (a TROP2-directed antibody-drug conjugate) plus pembrolizumab and chemotherapy to a pembrolizumab-chemotherapy regimen as neoadjuvant treatment. Enrolling patients with high-risk,…
NCT06966700 Registrational - New trial
Breast cancer
Phase II: Trastuzumab (HER2-directed mAb) trial combining surgery, radiation, and SBRT for HER2+ breast cancer
This randomized study assesses whether adding surgery, locoregional radiation therapy, and SBRT to standard systemic treatment (trastuzumab, a HER2-directed antibody; pertuzumab, another HER2 inhibitor; and…
NCT07053085 Exploratory - New trial Spotlight
Non-small cell lung cancer
Phase 2 Trial of Raludotatug deruxtecan ADC targeting CDH6
In this randomized umbrella study under a pembrolizumab master protocol, participants with previously treated Stage IV squamous NSCLC receive treatments every 3 weeks until disease progression. Investigational arms…
NCT06780098 Exploratory - New trial
Non-small cell lung cancer
Phase 1 NK-102: Umbilical Cord Blood NK Cells with Soluble IL-15 & PD-L1 Expression
This Phase 1 dose escalation trial by University of California, Irvine examines the safety and maximum tolerated dose of NK-102, an engineered natural killer cell therapy expressing soluble IL-15 and PD-L1,…
NCT07053007 First-in-human - New trial
Non-small cell lung cancer
Phase 2 Tiragolumab (TIGIT mAb) and Ivonescimab (PD-1/VEGF bispecific) trial in lung SCC.
This Phase 2 study at M.D. Anderson Cancer Center evaluates the combination of tiragolumab—a TIGIT-directed monoclonal antibody—and ivonescimab—a bispecific antibody targeting PD-1 and VEGF—in patients with…
NCT07038915 Exploratory - New trial
Small cell lung cancer
Phase III BNT327 VEGFA-directed mAb trial in extensive-stage small cell lung cancer
This randomized, double-blinded study compares two treatment arms in first-line extensive-stage small cell lung cancer patients. One arm uses atezolizumab—a PD-L1 inhibitor—plus etoposide (a topoisomerase II…
NCT06712355 Registrational - New trial Spotlight
Pancreatic cancer
Phase I/IIa Trial of E-EDV-D682 Nanocells Targeting EGFR in Metastatic PDAC
This randomized study compares the efficacy and safety of E-EDV-D682/GC nanocells in combination with gemcitabine (a ribonucleoside reductase inhibitor) and nab-paclitaxel (a tubulin inhibitor) versus standard…
NCT07049055 First-in-human - New trial
Pancreatic cancer
Phase 2 trial: Gemcitabine (ribonucleotide reductase inhibitor) and Nab-paclitaxel (tubulin inhibitor) alternating with mFOLFIRINOX
This study evaluates the safety and effectiveness of alternating Gemcitabine plus Nab-paclitaxel with mFOLFIRINOX as neoadjuvant treatment for borderline resectable pancreatic ductal adenocarcinoma. Patients must…
NCT07043270 Exploratory - New trial
Pancreatic cancer
Phase 1 Pilot: Paclitaxel (tubulin inhibitor) and NALIRIFOX in PDAC with peritoneal carcinomatosis
This trial by the University of Colorado, Denver evaluates safety and early efficacy of combining intraperitoneal paclitaxel with intravenous NALIRIFOX, a multi-agent chemotherapy regimen, in adults with pancreatic…
NCT07030283 Exploratory - New trial Spotlight
Melanoma
Phase 2 trial: V940 mRNA cancer vaccine & Pembrolizumab PD-1 inhibitor in advanced melanoma
This Phase 2 study evaluates whether a patient-specific TAA mRNA vaccine (V940) given by IM injection alongside IV pembrolizumab (a PD-1 inhibitor) can prolong progression-free survival compared to placebo plus…
NCT06961006 Exploratory - New trial
Melanoma
Phase 2 anti-PD-1 checkpoint inhibitor trial comparing selective vs therapeutic lymph node dissection in melanoma
This study aims to determine non-inferiority in 2-year recurrence-free survival among Stage III melanoma patients receiving neoadjuvant anti-PD-1 immunotherapy (a checkpoint inhibitor that reactivates immune…
NCT07049276 Exploratory - New trial
Ovarian cancer
Phase I/II saruparib PARP1 inhibitor trial
This master protocol study, sponsored by AstraZeneca, evaluates novel biomarker-guided anticancer treatments in participants with advanced/recurrent ovarian, fallopian tube, or primary peritoneal cancer. In Substudy…
NCT07060365 First-in-human - New trial
Bladder and urothelial cancer
Phase III trial: Gemcitabine DNA synthesis inhibitor plus intravesical BCG for recurrent bladder cancer
This randomized Phase III trial, sponsored by Alliance for Clinical Trials in Oncology and conducted at multiple US sites, evaluates whether adding gemcitabine—a ribonucleotide reductase inhibitor that blocks DNA…
NCT07000084 Registrational - New trial
Bladder and urothelial cancer
Phase II Study Enfortumab Vedotin (Nectin-4 ADC) Consolidative Surgery in Locally Advanced Urothelial Carcinoma
This phase II trial evaluates consolidative extirpative surgery for patients with locally advanced or oligo-metastatic urothelial carcinoma who achieved disease control with enfortumab vedotin-based systemic therapy.…
NCT07048457 Exploratory - New trial
Bladder and urothelial cancer
Phase II study: Gemcitabine (ribonucleotide reductase inhibitor) and Carboplatin (platinum inhibitor) in urothelial carcinoma
This Phase II trial at Fox Chase Cancer Center evaluates the efficacy and safety of gemcitabine plus carboplatin in patients with advanced urothelial carcinoma who have progressed following enfortumab vedotin and…
NCT07043972 Exploratory - New trial
Bladder and urothelial cancer
Phase 1/2 Trial of Nadofaragene Firadenovec, IFN-alpha2b Expressing Adenovirus Gene Therapy
This open-label, single-arm study led by Ferring Pharmaceuticals evaluates safety and tolerability of nadofaragene firadenovec in adult patients with low-grade upper tract urothelial carcinoma, including papillary…
NCT06668493 Exploratory - New trial
Prostate cancer
Phase 1/2 study of GSK5458514, a PSMA-targeting T cell engager for prostate cancer.
This study investigates the safety, tolerability, and dosing of GSK5458514 monotherapy in adults with metastatic castration-resistant prostate cancer across a two-part open-label design featuring dose escalation and…
NCT06990880 First-in-human - New trial
Prostate cancer
Phase I/II Trial of 225Ac-PSMA-R2, PSMA-targeted alpha therapy.
This open-label study by Novartis evaluates the safety, tolerability, and anti-tumor activity of 225Ac-PSMA-R2—a PSMA-targeted alpha emitter—in men with metastatic castration-resistant and hormone-sensitive prostate…
NCT05983198 First-in-human
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.